pd lecture atnc
DESCRIPTION
Parkinson's disease lecture. A lecture regarding this common neurodegenerative condition affecting movementTRANSCRIPT
![Page 1: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/1.jpg)
Parkinson’s diseaseParkinson’s disease
AskTheNeurologist.ComAskTheNeurologist.Com
Author AnonAuthor Anon
![Page 2: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/2.jpg)
AskTheNeurologist.Com
Essay on the shaking palsyEssay on the shaking palsyJames Parkinson 1817James Parkinson 1817
“involuntary tremulous motion,with lessened muscular power, in part not in action and even when supported ;with a propensity to bend the trunk forward, and to pass from a walking to a running pace , the senses and intellect being uninjured”
![Page 3: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/3.jpg)
AskTheNeurologist.Com
PathologyPathologyLoss of pigmented cells in substantia nigra
Intracellular cytoplasmic inclusion bodies ( Lewy bodies )
![Page 4: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/4.jpg)
AskTheNeurologist.Com
Parkinson disease is characterised by loss of Dopaminergic cells in the substantia nigra leading to abnormal activity in the basal ganglia as a whole
This leads to
-A decrease in the activity of the direct GABAergic pathway
-An increase in the activity of the indirect GABAergic pathway
![Page 5: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/5.jpg)
AskTheNeurologist.Com
![Page 6: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/6.jpg)
AskTheNeurologist.Com
![Page 7: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/7.jpg)
AskTheNeurologist.Com
Uptake of radio-labelled L-Dopa in striatum of normal compared to PD brain
![Page 8: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/8.jpg)
AskTheNeurologist.Com
Clinical FeaturesClinical Features
T
R
A
P
Tremor
Rigidity
Akinesia / Bradykinesia
Postural instability
![Page 9: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/9.jpg)
AskTheNeurologist.Com
Micrographia
=manifestation of bradykinesia
![Page 10: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/10.jpg)
AskTheNeurologist.Com
![Page 11: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/11.jpg)
AskTheNeurologist.Com
Overview of drug treatmentOverview of drug treatment
1. L-Dopa ( bypass rate limiting stem of Dopamine synthesis)
2. Dopamine agonists ( direct effect on striatum )
3. COMT inhibitors ( less peripheral inactivation of L-Dopa )
4. Selegeline ( MAOb) inhibitor ? Neuroprotective
5. Muscarinic antagonists ( act on striatal interneurons)
6. Amantadine ( mechanism unclear ? Dopamine release )
![Page 12: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/12.jpg)
AskTheNeurologist.Com
Treatment strategies Treatment strategies
1. The conservative approach
2. The neuroprotective approach
3. The symptomatic approach
![Page 13: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/13.jpg)
AskTheNeurologist.Com
Conservative approachConservative approach
1. Avoid all drugs until symptoms are troublesome
2. When symptoms become troublesome start amantadine and an anticholinergic
3. When symptoms become disabling introduce L-Dopa or agonists at minimal doses
![Page 14: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/14.jpg)
AskTheNeurologist.Com
Neuroprotective approachNeuroprotective approach
1. All newly diagnosed cases should be started on Selegeline
2. When symptoms become disabling add dopaminergic drugs
![Page 15: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/15.jpg)
AskTheNeurologist.Com
Symptomatic approachSymptomatic approach
At diagnosis treatment immediately started with dopaminergic drugs
Treatment continually modified in order to maintain maximum function for the maximum amount of time
![Page 16: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/16.jpg)
AskTheNeurologist.Com
Clinical fluctuations in PDClinical fluctuations in PDConditionCondition ManagementManagement
Wearing-off of L-Dopa effectWearing-off of L-Dopa effect Decrease between dose Decrease between dose intervalinterval
Sustained release L-DopaSustained release L-Dopa
Add DA agonistAdd DA agonist
Increase dose Increase dose
Add COMT inhibitorAdd COMT inhibitor
Delayed onset of responseDelayed onset of response Ensure L-Dopa not given with Ensure L-Dopa not given with protein.protein.
Give antacidsGive antacids
“ “ Off ” periodsOff ” periods Increase dose of L-DopaIncrease dose of L-Dopa
Increase dose frequencyIncrease dose frequency
Give before mealsGive before meals
On-Off phenomenonOn-Off phenomenon Very difficult to treatVery difficult to treat
Sustained release Sustained release preparationspreparations
![Page 17: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/17.jpg)
AskTheNeurologist.Com
Dyskinesias in PDDyskinesias in PDTypeType ManagementManagement
Peak-dose dyskinesiaPeak-dose dyskinesia Decrease each dose of L-Decrease each dose of L-DopaDopa
Add Dopamine agonistAdd Dopamine agonist
Add amantadineAdd amantadine
MyoclonusMyoclonus ClonazepamClonazepam
Decrease L-DopaDecrease L-Dopa
![Page 18: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/18.jpg)
AskTheNeurologist.Com
Psychosis in PDPsychosis in PD
Increased incidence in
- Elderly
- Pre-existing psychiatric conditions
Should only use atypical antipsychotic medications….in particular
CLOZAPINE - needs monitoring of white cell count
QUETIAPINE- no monitoring necessary
- now possibly drug of choice
![Page 19: PD lecture Atnc](https://reader034.vdocuments.net/reader034/viewer/2022052618/55494405b4c905144d8b54ca/html5/thumbnails/19.jpg)
AskTheNeurologist.Com
The EndThe End
AskTheNeurologist.CoAskTheNeurologist.Comm
Author AnonAuthor Anon